These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32997576)

  • 1. Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.
    Castro Mendez L; Martell K; Crook JM
    J Clin Oncol; 2020 Nov; 38(32):3820-3821. PubMed ID: 32997576
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.
    Kollmeier MA; McBride S; Gorovets D; Zelefsky MJ
    J Clin Oncol; 2020 Nov; 38(32):3821-3822. PubMed ID: 32997577
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial Comment to High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Martell K
    Int J Urol; 2020 Sep; 27(9):806-807. PubMed ID: 32700417
    [No Abstract]   [Full Text] [Related]  

  • 4. Can Extreme Dose Escalation With External Beam Radiation Therapy and Low-Dose-Rate Brachytherapy Boost Obviate the Need for Long-Term Androgen Deprivation Therapy in Patients With High-Risk Localized Prostate Cancer?
    King MT; Orio PF; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):402-403. PubMed ID: 38220257
    [No Abstract]   [Full Text] [Related]  

  • 5. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate-risk prostate cancer group without a Gleason score of 4 + 3: a single Japanese institutional experience.
    Okihara K; Kobayashi K; Iwata T; Naitoh Y; Kamoi K; Kawauchi A; Yamada K; Miki T
    Int J Urol; 2014 Mar; 21(3):271-6. PubMed ID: 24033545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer.
    Crook J
    Lancet Oncol; 2022 May; 23(5):558-560. PubMed ID: 35427473
    [No Abstract]   [Full Text] [Related]  

  • 8. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
    Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
    J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy: Brachytherapy as Dose Escalation for Localized Prostate Cancer.
    Pisansky TM
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1071-1073. PubMed ID: 36922081
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer.
    Ghadjar P; Böhmer D; Höcht S; Sedlmayer F; Wiegel T
    J Clin Oncol; 2020 May; 38(15):1746. PubMed ID: 32209006
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
    Krauss D; Kestin L; Ye H; Brabbins D; Ghilezan M; Gustafson G; Vicini F; Martinez A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1064-71. PubMed ID: 20584576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
    Pickles T; Morris WJ; Keyes M
    Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. Preliminary results.
    Martin T; Hey-Koch S; Strassmann G; Kolotas C; Baltas D; Rogge B; Röddiger S; Vogt HG; Heyd R; Dannenberg T; Kurek R; Tunn U; Zamboglou N
    Strahlenther Onkol; 2000 Aug; 176(8):361-7. PubMed ID: 10987019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
    Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
    Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.